Novo Cuts Outlook Once Again, Highlighting Obesity Struggles
Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new chief executive. Revenue will rise only as much…